Evercore ISI downgraded AN2 Therapeutics to Underperform from In Line with a $2 price target. AN2 is discontinuing the epetraborole Phase 2/3 program in NTM after seeing lack of efficacy on culture conversion and while disappointing, this is “not surprising news” after its voluntary pause of the Phase 3 back in February based on lower-than-expected efficacy, the analyst tells investors. At this point, the firm doesn’t see much revenue potential from the other indications, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANTX:
Questions or Comments about the article? Write to editor@tipranks.com